From Medscape Special Reports

Special Report: Inhaled Insulin

August 13, 2014

Latest News

Inhaled Insulin Coming Soon
A deal between the manufacturer and Sanofi-Aventis should make Afrezza available in the United States next year

FDA Approves Inhaled Insulin Afrezza for Diabetes
The FDA approved the short-acting inhaled insulin product Afrezza for both type 1 and type 2 diabetes, but not for smokers or patients with chronic lung disease.


Is Inhaled Insulin a 'Game Changer'?
The anticipated arrival of Afrezza, a new insulin product delivered via inhaler, is generating both excitement and skepticism.

Inhaled Insulin: What to Tell Patients
Get ready to answer patients' questions about Afrezza, a new inhaled-insulin product.

Drug and Disease Clinical Information

Afrezza Dosing and Drug Information

Editor's Note

Many patients with diabetes may prefer an inhaler over an injection when it comes to administering their needed insulin, and a new business deal may make that option available sooner than expected. Our collection provides all of the information you need to address patients' questions.
– Christine Wiebe, Editorial Director, Medscape Diabetes & Endocrinology

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.